Bionomics Limited (BNO.AX)

0.0240 -0.0010 (-4.00%) At close: 04:10PM AEDT

Bionomics Limited

200 Greenhill Road
Eastwood, SA 5063
Australia
61 8 8150 7400
https://www.bionomics.com.au

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Adrian Hinton BEC, F.C.A.	Acting Chief Financial Officer	323.78k	N/A	1952
Mr. Connor Bernstein M.Sc.	VP of Strategy & Corp. Devel.	344.98k	N/A	1988
Dr. Spyridon Papapetropoulos M.D., Ph.D.	CEO, Pres & Director	N/A	N/A	1974
Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D.	Consultant Chief Medical Officer of Clinical Neuroscience	N/A	N/A	N/A
Ms. Suzanne Irwin B.Com., FCIS	Company Sec.	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Corporate governance

Bionomics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.